1. Clinical and economic evaluation of a proteomic biomarker preterm birth risk predictor: cost-effectiveness modeling of prenatal interventions applied to predicted higher-risk pregnancies within a large and diverse cohort
- Author
-
Burchard, Julja, Markenson, Glenn R, Saade, George R, Laurent, Louise C, Heyborne, Kent D, Coonrod, Dean V, Schoen, Corina N, Baxter, Jason K, Haas, David M, Longo, Sherri A, Sullivan, Scott A, Wheeler, Sarahn M, Pereira, Leonardo M, Boggess, Kim A, Hawk, Angela F, Crockett, Amy H, Treacy, Ryan, Fox, Angela C, Polpitiya, Ashoka D, Fleischer, Tracey C, Garite, Thomas J, Boniface, J Jay, Zupancic, John AF, Critchfield, Gregory C, and Kearney, Paul E
- Subjects
Epidemiology ,Economics ,Applied Economics ,Health Sciences ,Infant Mortality ,Pediatric ,Prevention ,Patient Safety ,Clinical Research ,Health Services ,Preterm ,Low Birth Weight and Health of the Newborn ,Perinatal Period - Conditions Originating in Perinatal Period ,Reproductive health and childbirth ,Good Health and Well Being ,Pregnancy ,Female ,Infant ,Newborn ,Humans ,Premature Birth ,Cost-Benefit Analysis ,Proteomics ,Gestational Age ,Biomarkers ,Premature birth ,preterm birth ,protein biomarker risk predictor ,biomarker ,blood ,clinical utility ,cost-effectiveness ,microsimulation model ,I ,I1 ,I10 ,I19 ,biomarker – blood ,Public Health and Health Services ,Psychology ,Health Policy & Services ,Applied economics - Abstract
ObjectivesPreterm birth occurs in more than 10% of U.S. births and is the leading cause of U.S. neonatal deaths, with estimated annual costs exceeding $25 billion USD. Using real-world data, we modeled the potential clinical and economic utility of a prematurity-reduction program comprising screening in a racially and ethnically diverse population with a validated proteomic biomarker risk predictor, followed by case management with or without pharmacological treatment.MethodsThe ACCORDANT microsimulation model used individual patient data from a prespecified, randomly selected sub-cohort (N = 847) of a multicenter, observational study of U.S. subjects receiving standard obstetric care with masked risk predictor assessment (TREETOP; NCT02787213). All subjects were included in three arms across 500 simulated trials: standard of care (SoC, control); risk predictor/case management comprising increased outreach, education and specialist care (RP-CM, active); and multimodal management (risk predictor/case management with pharmacological treatment) (RP-MM, active). In the active arms, only subjects stratified as higher risk by the predictor were modeled as receiving the intervention, whereas lower-risk subjects received standard care. Higher-risk subjects' gestational ages at birth were shifted based on published efficacies, and dependent outcomes, calibrated using national datasets, were changed accordingly. Subjects otherwise retained their original TREETOP outcomes. Arms were compared using survival analysis for neonatal and maternal hospital length of stay, bootstrap intervals for neonatal cost, and Fisher's exact test for neonatal morbidity/mortality (significance, p
- Published
- 2022